Adeno-associated virus-mediated gene delivery.
Several gene delivery vehicles are being developed for somatic gene therapy and each of these vectors has unique properties which makes them appropriate for different human disease applications. Recombinant adeno-associated viral (rAAV) vectors are proving themselves to be safe and efficacious for the long-term expression of proteins and correction of genetic diseases following a single administration. The increasing number of tissues and diseases being targeted with rAAV vectors demonstrates their versatility and has resulted in different approaches for enhancing vector performance. Improving the methods for large-scale manufacturing, and accumulating safety and efficacy data in animals and humans are areas of intense research.
Snyder
R O
RO
Division of Molecular Medicine, Children's Hospital, Boston, USA. rsnyder@hihg.med.harvard.edu
D000818:Animals; D001709:Biotechnology; D000229:Dependovirus / Q000235:genetics*; D018014:Gene Transfer Techniques; D005818:Genetic Engineering; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D011995:Recombination, Genetic